No Picture
Trading Ideas

Amazon's faster shipping dents profits, more pain to come

Amazon’s fourth-quarter cost for one-day shipping will be nearly double the $800 million the company spent during the second quarter, Chief Financial Officer Brian Olsavsky said on a call with reporters. Carriers like United Parcel Service Inc charge more for faster delivery, but that is only one component of the cost increase at Amazon, which ships around 10 billion packages per year. Logistics experts, who noted that volumes surge during the holiday season, took Amazon’s shipping cost forecast in stride. …read more […]

No Picture
Trading Ideas

Albemarle cuts 2019 forecast on lithium price pressure

Demand for lithium, a key component of batteries used in cell phones, electric vehicles and other consumer goods, is widely expected to spike by 2025. Albemarle also trimmed its 2019 net sales forecast range to $3.6 billion to $3.7 billion, from $3.65 billion to $3.85 billion. The company also reported preliminary third quarter adjusted profit of $1.53 per share hit by weakness in its lithium unit, which offset results from its bromine and catalysts units. …read more […]

No Picture
Trading Ideas

UPDATE 1-Albemarle cuts 2019 forecast on lithium price pressure

Albemarle Corp, the world’s largest lithium producer, on Thursday cut its sales and profit forecasts for the year, hit by a continued slump in prices for the white metal, sending its shares down nearly 7% in extended trading. Demand for lithium, a key component of batteries used in cell phones, electric vehicles and other consumer goods, is widely expected to spike by 2025. Albemarle also trimmed its 2019 net sales forecast range to $3.6 billion to $3.7 billion, from $3.65 billion to $3.85 billion. …read more […]

No Picture
Trading Ideas

FTC staff recommends approval of Roche deal for Spark: report

The Federal Trade Commission staff reviewing Roche’s plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday. Basel-based Roche, the biggest maker of cancer drugs, said in February that it would buy the U.S. company, acquiring a portfolio that includes a blindness treatment that has U.S. and European approval and other projects for neurodegenerative disorders like Huntington’s disease. One of its projects is a gene therapy treatment for hemophilia. …read more […]